XTL Biopharmaceuticals Board Changes
Ticker: XTLB · Form: 6-K · Filed: Oct 23, 2025 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Oct 23, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, management-change
Related Tickers: XTLB
TL;DR
XTL Bio board seat opens, CEO steps in.
AI Summary
Doron Turjeman resigned from the Board of Directors of XTL Biopharmaceuticals Ltd. on October 21, 2025, for personal reasons. Noam Band, the CEO, was appointed to the Board of Directors to fill the vacancy.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, which may impact investor confidence.
Risk Assessment
Risk Level: low — This filing reports a routine board resignation and appointment, with no indication of financial distress or significant strategic shifts.
Key Players & Entities
- Doron Turjeman (person) — Resigned from the Board of Directors
- XTL Biopharmaceuticals Ltd. (company) — Company filing the report
- Noam Band (person) — Appointed to the Board of Directors
- October 21, 2025 (date) — Effective date of resignation and appointment
FAQ
Who resigned from the XTL Biopharmaceuticals Ltd. Board of Directors?
Doron Turjeman resigned from the Board of Directors.
When did Doron Turjeman's resignation become effective?
Doron Turjeman's resignation was effective October 21, 2025.
What was the reason for Doron Turjeman's resignation?
Doron Turjeman resigned due to personal reasons.
Was Doron Turjeman's resignation due to a disagreement with the company?
No, the filing states that Mr. Turjeman's resignation was not the result of any disagreement with the Company or its management.
Who was appointed to the Board of Directors in place of Doron Turjeman?
Noam Band, the Company Chief Executive Officer, was appointed to serve as a member of the Board of Directors in his place.
Filing Stats: 280 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2025-10-23 16:00:14
Filing Documents
- ea0262263-6k_xtlbio.htm (6-K) — 11KB
- 0001213900-25-101642.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XTL BIOPHARMACEUTICALS LTD. Date: October 22, 2025 By: /s/ Shlomo Shalev Chairman of the Board of Directors 2